Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells

Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells

BackgroundTreatment of B-cell malignancies with CD19-directed chimeric antigen receptor (CAR) T-cells marked a new era in immunotherapy, which yet has to be successfully adopted to solid cancers. Epigenetic inhibitors of DNA methyltransferases (DNMTi) and histone deacetylases (HDACi) can induce broa...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Camilla M. Grunewald, Corinna Haist, Carolin König, Patrick Petzsch, Arthur Bister, Elfriede Nößner, Constanze Wiek, Kathrin Scheckenbach, Karl Köhrer, Günter Niegisch, Helmut Hanenberg, Michèle J. Hoffmann
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
epigenetic inhibitors
bladder cancer
chimeric antigen receptor
immunotherapy
T-cell
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/512c4135cac04c4ea5c0bf21f0fa8e19
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/512c4135cac04c4ea5c0bf21f0fa8e19

Ejemplares similares